View Exam | PowerPak

1. Which of the following best describes the relationship between PD-L1 expression and treatment response in patients treated with nivolumab?

A. Higher levels of PD-L1 expression in patients are associated with poorer response rates. B. Higher PD-L1 expression in patients is associated with increased risk of hemorrhagic complications. C. PD-L1 expression in patients is associated with treatment response in nonsquamous non-small–cell lung cancer but not in patients with squamous cell carcinoma. D. PD-L1 expression in patients are not associated with treatment response.

2. Which of the following requires the use of an US Food and Drug Administration-approved companion test for PD-L1 expression?

A. Nivolumab B. Pembrolizumab C. Bevacizumab D. Ipilimumab

3. According to immune-related response criteria, progressive disease is confirmed twice, at least ________ apart in the absence of clinical deterioration.

A. 2 weeks B. 4 weeks C. 2 months D. 4 months

4. Which of the following adverse events would be most commonly encountered in a patient receiving immunotherapy?

A. Nausea, vomiting B. Diarrhea, colitis, skin toxicities C. Hemorrhage D. Sedation, lethargy

5. A 58-year-old woman started treatment with an immune checkpoint inhibitor to treat metastatic non-small–cell lung cancer. Her tumor mass increased during the first 4 weeks but then decreased at subsequent evaluations at 8 and 12 weeks. Now at 15 weeks, she has developed severe (grade 3) diarrhea. Which of the following treatment strategies should her pharmacist recommend for this patient?

A. Continue treatment and add symptomatic management for diarrhea B. Reduce her dose by 50% and add symptomatic management for diarrhea C. Discontinue her treatment D. Discontinue her treatment and start her on high-dose steroids (eg, 1 mg/kg per day prednisolone)

6. Which of the following drug-related adverse event, would you EXPECT to have the shortest time to onset following initiation of nivolumab therapy?

A. Skin toxicities B. Gastrointestinal effects C. Hepatic effects D. Renal effects

7. For a patient who develops a complete response while receiving immune checkpoint therapy, how long should her pharmacist recommend that treatment be continued?

A. 3 months B. 6 months C. 12 months D. Until disease progression or unacceptable toxicity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following best describes the relationship between PD-L1 expression and treatment response in patients treated with nivolumab?

2. Which of the following requires the use of an US Food and Drug Administration-approved companion test for PD-L1 expression?

3. According to immune-related response criteria, progressive disease is confirmed twice, at least ________ apart in the absence of clinical deterioration.

4. Which of the following adverse events would be most commonly encountered in a patient receiving immunotherapy?

6. Which of the following drug-related adverse event, would you EXPECT to have the shortest time to onset following initiation of nivolumab therapy?

7. For a patient who develops a complete response while receiving immune checkpoint therapy, how long should her pharmacist recommend that treatment be continued?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following best describes the relationship between PD-L1 expression and treatment response in patients treated with nivolumab?

2. Which of the following requires the use of an US Food and Drug Administration-approved companion test for PD-L1 expression?

3. According to immune-related response criteria, progressive disease is confirmed twice, at least ________ apart in the absence of clinical deterioration.

4. Which of the following adverse events would be most commonly encountered in a patient receiving immunotherapy?

6. Which of the following drug-related adverse event, would you EXPECT to have the shortest time to onset following initiation of nivolumab therapy?

7. For a patient who develops a complete response while receiving immune checkpoint therapy, how long should her pharmacist recommend that treatment be continued?

« Return to Activity

Customers who Purchased
this Activity also Purchased